Key result
End-stage renal disease significantly increased the risk of stroke, systemic embolization, or death in patients undergoing left atrial appendage occlusion (HR 5.12; 95% CI 1.4-18.6; p=0.013).
Why the study?
The efficacy of thromboembolic prevention using LAAO in patients with AF and ESRD had rarely been reported in Asian populations.
Does left atrial appendage occlusion (LAAO) result in different long-term outcomes in patients with atrial fibrillation and ESRD compared to those without ESRD?
Cohort (n=310)
Yes
Does left atrial appendage occlusion (LAAO) result in different long-term outcomes in patients with atrial fibrillation and ESRD compared to those without ESRD?
Hazard Ratio: 5.12 (95% CI 1.4–18.6)
p-value: p=0.013
In Asian patients with AF, LAAO therapy is associated with less favorable long-term outcomes, including higher mortality and device-related thrombosis, in those with ESRD on dialysis compared to those without ESRD.
First Asian long-term LAAO data in AF-ESRD on dialysis; hypothesis-generating and should not yet change practice.
OBJECTIVE: In patients with atrial fibrillation (AF) and end-stage renal disease (ESRD), oral anticoagulants are contraindicated, and left atrial appendage occlusion (LAAO) is an alternative treatment. However, the efficacy of thromboembolic prevention using LAAO in these patients has rarely been reported in Asian populations. To our knowledge, this is the first long-term LAAO study in patients with AF undergoing dialysis in Asia. METHODS: In this study, 310 patients (179 men) with a mean age of 71.3 ± 9.6 years and mean CHA2DS2-VASc 4.2 ± 1.8 were consecutively enrolled at multiple centers in Taiwan. The outcomes of 29 patients with AF and ESRD undergoing dialysis who underwent LAAO were compared to those without ESRD. The primary composite outcomes were stroke, systemic embolization, or death. RESULTS: No difference in mean CHADS-VASc score was noted between patients with versus without ESRD (4.1 ± 1.8 vs. 4.6 ± 1.9, p = 0.453). After a mean follow-up of 38 ± 16 months, the composite endpoint was significantly higher in patients with ESRD (hazard ratio, 5.12 [1.4-18.6]; p = 0.013) than in those without ESRD after LAAO therapy. Mortality was also higher in patients with ESRD (hazard ratio, 6.6 [1.1-39.7]; p = 0.038). The stroke rate was numerically higher in patients with versus without ESRD, but the difference was not statistically significant (hazard ratio, 3.2 [0.6-17.7]; p = 0.183). Additionally, ESRD was associated with device-related thrombosis (odds ratio, 6.15; p = 0.047). CONCLUSION: Long-term outcomes of LAAO therapy may be less favorable in patients with AF undergoing dialysis, possibly because of the poor condition of patients with ESRD.
No takes yet. Share an insight, caveat, or question.
Chang et al. (2023) conducted a cohort in Atrial fibrillation (n=310). End-stage renal disease (ESRD) vs. Without ESRD was evaluated on Stroke, systemic embolization, or death (HR 5.12, 95% CI 1.4-18.6, p=0.013). End-stage renal disease significantly increased the risk of stroke, systemic embolization, or death in patients undergoing left atrial appendage occlusion (HR 5.12; 95% CI 1.4-18.6; p=0.013).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: